The long-acting β2-agonist salmeterol xinafoate: Effects on airway inflammation in asthma

European Respiratory Journal

Volumn 14, Issue 2, 1999, Pages 275-282

  Roberts, J A ^a   Bradding, P ^a,b   Britten, K M ^a   Walls, A F ^a   Wilson, S ^a   Gratziou, C ^a   Holgate, S T ^a   Howarth, P H ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b GLENFIELD HOSPITAL   (United Kingdom)

Author keywords

agonists; Asthma; Bronchial biopsy; Bronchial inflammation; Bronchoscopy; Salmeterol xinafoate

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; METHACHOLINE; PLACEBO; SALMETEROL XINAFOATE; AUTACOID; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; DRUG DERIVATIVE; SALBUTAMOL; SALMETEROL;

ADULT; AIRWAY; ARTICLE; ASTHMA; BRONCHODILATATION; BRONCHOSCOPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; INFLAMMATION; INHALATIONAL DRUG ADMINISTRATION; LUNG LAVAGE; MALE; METERED DOSE INHALER; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; ADOLESCENT; IMMUNOLOGY; MIDDLE AGED; RESPIRATORY TRACT ALLERGY; T LYMPHOCYTE;

ADOLESCENT; ADRENERGIC BETA-AGONISTS; ADULT; ALBUTEROL; ASTHMA; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHODILATOR AGENTS; BRONCHOSCOPY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; RESPIRATORY HYPERSENSITIVITY; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 0032589395     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3003.1999.14b07.x     Document Type: Article

References (34)

1. Djukanovic R, Roche WR, Wilson JW, et al. Mucosal inflammation in asthma. Am Rev Respir Dis 1990; 142: 434-457.
2. Dunnill MS. The pathology of asthma with special reference to changes in the bronchial mucosa. J Clin Pathol 1960; 13: 27-33.
3. Ullman A, Svedmyr N. Salmeterol, a new long acting inhaled beta 2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients. Thorax 1988; 43: 674-678.
4. Twentyman OP, Finnerty JP, Harris A, Palmer J, Holgate ST. Protection against allergen-induced asthma by salmeterol. Lancet 1990; 336: 1338-1342.
5. Butchers PR, Vardey CJ, Johnson M. Salmeterol: a potent and long acting inhibitor of inflammatory mediator release from human lung. Br J Pharm 1991; 104: 672-676.
6. Whelan CJ, Johnson M. Inhibition by salmeterol of increased vascular permeability and granulocyte accumulation in guinea-pig lung and skin. Br J Pharmacol 1992; 105: 831-838.
7. Crane J, Pearce N, Flatt A, et al. Prescribed fenoterol and death from asthma in New Zealand. Lancet 1989; i: 917-922.
8. Spitzer WO, Suissa S, Ernst P, et al. The use of β-agonists and the risk of death and near-death from asthma. N Engl J Med 1992; 326: 501-506.
9. Sears MR, Taylor DR, Print CG, et al. Regular inhaled beta agonist treatment in bronchial asthma. Lancet 1990; 336: 1391-1396.
10. Vathenen AS, Knox AJ, Higgins BG, Britton JR, Tattersfield AE. Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline. Lancet 1988; i: 554-558.
11. van Schayck CP, Dompeling E, van Herwaarden CLA, et al. Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand? A randomised controlled study. BMJ 1991; 303: 1426-1431.
12. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994; 334: 219-224.
13. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153: 1481-1488.
14. Pauwels RA, Claes-Goran L, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337: 1405-1411.
15. Gardiner PV, Ward C, Booth H, Allison A, Hendrick DJ, Walters EH. Effect of eight weeks treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics. Am J Respir Crit Care Med 1994; 150: 1006-1011.
16. Chai H, Farr RS, Froelich LA, et al. Standardisation of bronchial inhalation challenge procedures. J Allergy Clin Immunol 1975; 56: 323-327.
17. Djukanovic R, Wilson JW, Lai CKW, Holgate ST, Howarth PH. The safety aspects of fibreoptic bronchoscopy, bronchoalveolar lavage, and endobronchial biopsy in asthma. Am Rev Respir Dis 1991; 143: 772-777.
18. NIH workshop summary and guidelines. Investigative use of bronchoscopy, lavage, and bronchial biopsies in asthma and other airways diseases. Eur Respir J 1992; 5: 115-121.
19. Gratziou C, Carroll M, Walls A, Howarth PH, Holgate ST. Early changes in T lymphocytes recovered by bronchoalveolar lavage after local allergen challenge of asthmatic airways. Am Rev Respir Dis 1992; 145: 1259-1264.
20. Kelly RW, Deam S, Cameron MJ, Seamark PF. Measurement by radioimmunoassay of prostaglandins as their methyl oximes. Prostaglandin Leukotr Med 1986; 24: 1-14.
21. Weeke B. Rocket immunoelectrophoresis. Scand J Immunol 1973; 1: 37-46.
22. Britten KM, Howarth PH, Roche WR. Immunohistochemistry on resin sections, a comparison of resin embedding techniques for small mucosal biopsies. Biotech Histochem 1993; 68: 271-280.
23. Walls AF, Bennett AR, McBride HM, Glennie MJ, Holgate ST, Church MK. Production and characterisation of monoclonal antibodies specific for human mast cell tryptase. Clin Exp Allergy 1990; 20: 581-589.
24. Spurr AR. A low viscosity epoxy resin embedding medium for electron microscopy. J Ultrastruct Res 1969; 26: 31-43.
25. Djukanovic R, Wilson JW, Britten KM, et al. The inhibitory effect of the inhaled corticosteroid beclomethasone dipropionate on airway mucosal mast cell and eosinophil numbers relates to its clinical efficacy in asthma. Am Rev Respir Dis 1990; 145: 669-674.
26. Anonynous. The British guidelines on asthma management: 1995 review and position statement. Thorax 1997; 52: Suppl. 1.
27. 2 adrenergic receptors in asthma: a current perspective. Lung 1992; 170: 125-141.
28. Church MK, Hiroi J. Inhibition of IgE-dependent histamine release from human dispersed lung mast cells by anti-allergic drugs and salbutamol. Br J Pharmacol 1987; 90: 421-429.
29. Mosberg B. Mucociliary transport and its influence by beta-adrenoceptor drugs. Acta Pharmacol Toxicol 1979; 44: 41-44.
30. Howarth PH, Durham SR, Lee TH, Kay AB, Church MK, Holgate ST. Influence of albuterol, cromolyn sodium and ipratropium bromide on the airway and circulating mediator responses to allergen provocation in asthma. Am Rev Respir Dis 1985; 132: 986-992.
31. Bradley BL, Azzawi M, Jacobson M, et al. Eosinophils, T-lymphocytes, mast cells, neutrophils, and macrophages in bronchial biopsy specimens from atopic subjects with asthma: Comparison with biopsy specimens from atopic subjects without asthma and normal control subjects and relationship to bronchial hyperresponsiveness. J Allergy Clin Immunol 1991; 88: 661-674.
32. Szefler SJ, Ando R, Cicutto LC, Surs W, Hill MR, Martin RJ. Plasma histamine, epinephrine, cortisol and leukocyte β-adrenergic receptors in nocturnal asthma. Clin Pharmacol Ther 1991; 49: 59-68.
33. 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med 1992; 327: 1198-1203.
34. 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomised, double-blind, parallel-group controlled trial. J Allergy Clin Immunol 1992; 90: 32-42.